Epstein-Barr virus infection leads to partial phenotypic reversion of terminally differentiated malignant B cells

Cancer Letters

Volumn 284, Issue 2, 2009, Pages 165-174

  Anastasiadou, Eleni ^a   Vaeth, Signe ^b   Cuomo, Laura ^c   Boccellato, Francesco ^a   Vincenti, Sara ^a   Cirone, Mara ^a   Presutti, Carlo ^a   Junker, Steffen ^b   Winberg, Gösta ^d   Frati, Luigi ^a   Wade, Paul A ^e   Faggioni, Alberto ^a   Trivedi, Pankaj ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b AARHUS UNIVERSITY   (Denmark)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Differentiation; EBV; Latency; Myeloma

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; HLA DR ANTIGEN; IMMUNOGLOBULIN LAMBDA CHAIN; INTERFERON REGULATORY FACTOR 4; SYNDECAN 1; TRANSCRIPTION FACTOR PAX5;

ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERTANT; TUMOR CELL; UPREGULATION; VIRUS CELL INTERACTION; VIRUS LATENCY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN LAMBDA-CHAINS; INTERFERON REGULATORY FACTORS; MICRORNAS; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM PROTEINS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SYNDECAN-1; TUMOR CELLS, CULTURED; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 69549119991     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.025     Document Type: Article

References (28)

1. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. 3 (2003) 801-812
2. Young L.S., and Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4 (2004) 757-768
3. Dong H.Y., Scadden D.T., de Leval L., Tang Z., Isaacson P.G., and Harris N.L. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am. J. Surg. Pathol. 29 (2005) 1633-1641
4. Kuze T., Nakamura N., Hashimoto Y., Sasaki Y., and Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn. J. Cancer Res. 91 (2000) 1233-1240
5. Knowles D.M. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol. Oncol. Clin. North. Am. 17 (2003) 785-820
6. Bell A.I., Groves K., Kelly G.L., Croom-Carter D., Hui E., Chan A.T., and Rickinson A.B. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J. Gen. Virol. 87 (2006) 2885-2890
7. Klein U., Gloghini A., Gaidano G., Chadburn A., Cesarman E., Dalla-Favera R., and Carbone A. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101 (2003) 4115-4121
8. Tcheng W.Y., Said J., Hall T., Al-Akash S., Malogolowkin M., and Feig S.A. Post-transplant multiple myeloma in a pediatric renal transplant patient. Pediatr. Blood Cancer 47 (2006) 218-223
9. Horenstein M.G., Nador R.G., Chadburn A., Hyjek E.M., Inghirami G., Knowles D.M., and Cesarman E. Epstein-Barr virus latent gene expression in primary effusin lymphomas containing Kapos's sarcoma associated herpesvirus/human herpesvirus-8. Blood 90 (1997) 1186-1192
10. Laichalk L.L., and Thorley-Lawson D.A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 79 (2005) 1296-1307
11. Trivedi P., Takazawa K., Zompetta C., Cuomo L., Anastasiadou E., Carbone A., Frati L., Takada K., and Faggioni A. Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency altered phenotype and increased tumorigenicity without affecting TCL1 expression. Blood 103 (2004) 313-316
12. Matsuoka Y., Moore G.E., Yagi Y., and Pressman D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. Med. 125 (1967) 1246-1250
13. Maruo S., Yang L., and Takada K. Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J. Gen. Virol. 82 (2001) 2373-2383
14. Shapiro-Shelef M., and Calame K. Regulation of plasma-cell development. Nat. Rev. Immunol. 5 (2005) 230-242
15. Piskurich J.F., Lin K.I., Lin Y., Wang Y., Ting J.P., and Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat. Immunol. 1 (2000) 526-532
16. Said J.W., Hoyer K.K., French S.W., Rosenfelt L., Garcia-Lloret M., Koh P.J., Cheng T.C., Sulur G.G., Pinkus G.S., Kuehl W.M., Rawlings D.J., Wall R., and Teitell M.A. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab. Invest. 81 (2001) 555-564
17. Pekarsky Y., Santanam U., Cimmino A., Palamarchuk A., Efanov A., Maximov V., Volinia S., Alder H., Liu C.G., Rassenti L., Calin G.A., Hagan J.P., Kipps T., and Croce C.M. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66 (2006) 11590-11593
18. Schebesta M., Pfeffer P.L., and Busslinger M. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity 17 (2002) 473-485
19. Trivedi P., Spinsanti P., Cuomo L., Volpe M., Takada K., Frati L., and Faggioni A. Differential regulation of Epstein-Barr virus latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain. J. Virol. 75 (2001) 4929-4935
20. Anastasiadou E., Boccellato F., Cirone M., Kis L.L., Klein E., Frati L., Faggioni A., and Trivedi P. Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein-Barr virus. Leukemia 19 (2005) 1854-1856
21. Arguello M., Sgarbanti M., Hernandez E., Mamane Y., Sharma S., Servant M., Lin R., and Hiscott J. Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene 22 (2003) 964-973
22. Tierney R., Nagra J., Hutchings I., Shannon-Lowe C., Altmann M., Hammerschmidt W., Rickinson A.B., and Bell A. Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. J. Virol. 81 (2007) 10092-100100
23. Babcock G.J., Hochberg D., and Thorley-Lawson D.A. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13 (2000) 497-506
24. Horenstein M.G., Nador R.G., Chadburn A., Hyjek E.M., Inghirami G., Knowles D.M., and Cesarman E. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 90 (1997) 1186-1191
25. Hopwood P.A., Brooks L., Parratt R., Hunt B.J., Bokhari M., Thomas J.A., Yacoub M., and Crawford D.H. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 74 (2002) 194-202
26. Pajic A., Staege M.S., Dudziak D., Schuhmacher M., Spitkovsky D., Eissner G., Brielmeier M., Polack A., and Bornkamm G.W. Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Int. J. Cancer 93 (2001) 810-816
27. Boccellato F., Anastasiadou E., Rosato P., Kempkes B., Frati L., Faggioni A., and Trivedi P. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodkin's lymphoma cells. J. Virol. 81 (2007) 2274-2282
28. Fujiwara S., Nitadori Y., Nakamura H., Nagaishi T., and Ono Y. Epstein-barr virus (EBV) nuclear protein 2-induced disruption of EBV latency in the Burkitt's lymphoma cell line Akata: analysis by tetracycline-regulated expression. J. Virol. 73 (1999) 5214-5219